Tandem Tipping Point
Xalkori and Zelboraf Prove Efficiency of RxDx Strategy
By Trista Morrison
Tuesday, September 6, 2011
For years, the drug industry has known its cost of developing a new product estimated at $1.3 billion is not sustainable. For years, companion diagnostics have been considered as a potential solution to that problem. And for years, the result has been a lot of talk, but very little action.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.